Stock MACK MERRIMACK PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Merrimack Pharmaceuticals, Inc.

Equities

MACK

US5903282094

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-17 pm EDT 		5-day change 1st Jan Change
15.13 USD -0.13% Intraday chart for Merrimack Pharmaceuticals, Inc. 0.00% +12.83%
May. 21 Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from S&P Global BMI Index CI
May. 21 Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from S&P TMI Index CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Payable on or About May 17, 2024
CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Merrimack Pharmaceuticals to Get $225 Million Milestone Payment After FDA's Supplemental NDA Approval
DJ
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
ETF Preview: ETFs, Stock Futures Down Pre-Bell After Mortgage Applications Report
MT
Merrimack Pharmaceuticals, Inc. Provides Ipsen Report That Onivyde Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021
CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020
CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020
CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MACK Stock
  4. News Merrimack Pharmaceuticals, Inc.
  5. Highlights